Home  |  Contact

Cellosaurus PEO6 (CVCL_2691)

[Text version]

Cell line name PEO6
Synonyms PE06; PEO-6
Accession CVCL_2691
Resource Identification Initiative To cite this cell line use: PEO6 (RRID:CVCL_2691)
Comments Doubling time: 77 hours (PubMed=3167863).
Omics: Deep RNAseq analysis.
Omics: Genome sequenced.
Sequence variations Hemizygous for BRCA2 p.Tyr1655Tyr (5193C>T); de novo mutation that cancels the 5193C>G mutation in the patient (PubMed=19654294).
TP53 p.Gly244Asp (c.731G>A) (PubMed=28273451).
Disease BRCA2 syndrome (NCIt: C36101)
Ovarian cystadenocarcinoma (NCIt: C5228)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_2686 ! PEO1
CVCL_2690 ! PEO4
Sex of cell Female
Age at sampling Age unspecified
Category Cancer cell line
STR profile Source(s): ECACC; PubMed=22710073; PubMed=30485824

Markers:
AmelogeninX
CSF1PO10,12
D2S133820,21
D3S135816
D5S81811,12
D7S82010
D8S117913,14
D13S31710
D16S5399
D18S5116
D19S43313,15
D21S1130 (PubMed=22710073)
30,32.2 (PubMed=30485824)
FGA20
TH019.3
TPOX9,11
vWA15,16

Run an STR similarity search on this cell line
Publications

PubMed=3167863
Langdon S.P., Lawrie S.S., Hay F.G., Hawkes M.M., McDonald A., Hayward I.P., Schol D.J., Hilgers J., Leonard R.C.F., Smyth J.F.
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Cancer Res. 48:6166-6172(1988)

PubMed=19654294; DOI=10.1158/0008-5472.CAN-09-1178
Sakai W., Swisher E.M., Jacquemont C., Chandramohan K.V., Couch F.J., Langdon S.P., Wurz K., Higgins J., Villegas E., Taniguchi T.
Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma.
Cancer Res. 69:6381-6386(2009)

PubMed=20581869; DOI=10.1038/onc.2010.245
Cooke S.L., Ng C.K.Y., Melnyk N., Garcia M.J., Hardcastle T., Temple J., Langdon S.P., Huntsman D.G., Brenton J.D.
Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma.
Oncogene 29:4905-4913(2010)

PubMed=22710073; DOI=10.1016/j.ygyno.2012.06.017
Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P.
DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination.
Gynecol. Oncol. 127:241-248(2012)

PubMed=23415752; DOI=10.1016/j.molonc.2012.12.007
Stordal B., Timms K., Farrelly A., Gallagher D., Busschots S., Renaud M., Thery J., Williams D., Potter J., Tran T., Korpanty G., Cremona M., Carey M.S., Li J., Li Y., Aslan O., O'Leary J.J., Mills G.B., Hennessy B.T.
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mol. Oncol. 7:567-579(2013)

PubMed=28273451; DOI=10.1016/j.celrep.2017.02.028
Medrano M., Communal L., Brown K.R., Iwanicki M., Normand J., Paterson J., Sircoulomb F., Krzyzanowski P., Novak M., Doodnauth S.A., Saiz F.S., Cullis J., Al-Awar R., Neel B.G., McPherson J., Drapkin R., Ailles L., Mes-Massons A.-M., Rottapel R.
Interrogation of functional cell-surface markers identifies CD151 dependency in high-grade serous ovarian cancer.
Cell Rep. 18:2343-2358(2017)

PubMed=30485824; DOI=10.1016/j.celrep.2018.10.096
Papp E., Hallberg D., Konecny G.E., Bruhm D.C., Adleff V., Noe M., Kagiampakis I., Palsgrove D., Conklin D., Kinose Y., White J.R., Press M.F., Drapkin R., Easwaran H., Baylin S.B., Slamon D., Velculescu V.E., Scharpf R.B.
Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines.
Cell Rep. 25:2617-2633(2018)

Cross-references
Cell line collections ECACC; 10032310
Ximbio; 151674
Cell line databases/resources Cell_Model_Passport; SIDM00470
Ontologies BTO; BTO:0005798
EFO; EFO_0005449
Gene expression databases GEO; GSM459855
GEO; GSM659400
GEO; GSM2475003
Other Wikidata; Q54947169
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number17